The Top Phase 3 Disasters of 2012

Source: Fierce Biotech, John Carroll (10/3/12)

"Drug development is a tough business. Sometimes, just when you think you're getting to the pot at the end of the rainbow, you find the trap door one step away."

Fierce Biotech, John Carroll

Drug development is a tough business. Sometimes, just when you think you're getting to the pot at the end of the rainbow, you find the trap door one step away.

It's not supposed to work that way. The further you get down the pipeline, the better your shot at success. By the end of Phase 2, investigators are supposed to have a solid set of significant safety and efficacy data on humans. Phase 3 is where the big bets are made, based on good science and some unprecedented demands for new products. . .View Full Article

Biotech to Fast Track Phase 3 Depression Trial
Source: Dr. Myles Minter (10/30/2025)

Alto Neuroscience Inc. (ANRO:NYSE) intends to carry out this newly added study, supported by a recent financing, and the previously planned Phase 2b trial simultaneously, noted a William Blair report.

Co. Speeds Up Development of New Drug for Depression
Source: Andrew Tsai (10/28/2025)

Alto Neuroscience Inc. (ANRO:NYSE) plans Phases 2b and 3 trials of its asset, ALTO-207, in treatment-resistant depression, noted a Jefferies report.

2 Key Catalysts Ahead for Developer of Psych Drugs
Source: Patrick Trucchio (10/28/2025)

Alto Neuroscience Inc. (ANRO:NYSE) expects to release topline trial data in 2025 and commence a separate study in 2026, noted an H.C. Wainwright & Co. report.

Price Target on Psychiatric Drug Biotech Boosted 200%
Source: Dr. Laura Chico (10/27/2025)

Alto Neuroscience Inc. (ANRO:NYSE) completed a US$50 million equity raise and announced plans to accelerate development of its recently acquired asset in treatment-resistant depression, noted a Wedbush report.

US Biopharma In-Licenses 3 New Assets
Source: Dr. Martin Fan (10/24/2025)

Zenas BioPharma Inc.'s (ZBIO:NASDAQ) target price is increased 14% to reflect the Phase 3 investigative multiple sclerosis drug included in this recent deal, noted a Wedbush report.